Glaukos Corp (GKOS) Stock Price, Quote & News

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 367 9600

Fax: 949 367 9984

Website: www.glaukos.com

Address:

One Glaukos Way, Aliso Viejo, United States

Kingofstocks0001 Feb. 24 at 2:43 PM

$GKOS fueled up

0 · Reply

Kingofstocks0001 Feb. 24 at 2:40 PM

$GKOS here comes the rocket

0 · Reply

VickieWaldron193 Feb. 21 at 7:37 AM

$GKOS Glaukos develops ophthalmic surgical devices. Growth depends on procedure adoption. Margins are strong.

0 · Reply

PaulLaurent Feb. 19 at 7:11 AM

🔥 Blaze Elliott Wave Scanner — February 19, 2026 Risk: 1–2% per trade $CABA (Tech, stable) Trig 3.12 | SL 2.81 | PT 3.73 | F51 V37 G70 Q48 VAL56 | News: recent fund positioning write-up; no fresh company PR. $CCOI (General, growth) Trig 29.95 | SL 26.96 | PT 35.94 | F38 V23 G70 Q27 VAL62 | News: no confirmed company-specific headline in the last 48h. $GKOS (Healthcare, growth) Trig 122.00 | SL 109.80 | PT 143.31 | F39 V0 G79 Q43 VAL54 | News: Q4 and FY25 results; raised 2026 net sales outlook to 600–620M. $GRPN (Tech, stable) Trig 13.57 | SL 12.21 | PT 16.28 | F51 V53 G67 Q36 VAL82 | News: no new press release posted on IR site in the last 48h. $TV (General, stable) Trig 3.49 | SL 3.14 | PT 4.18 | F72 V100 G50 Q64 VAL80 | News: recent coverage flagged Benchmark Buy and 10 target.

0 · Reply

silkroad58 Feb. 18 at 11:38 PM

$CCJ $NBIS $ICLR $GKOS $SPY Your picks are a day late and a dollar short. Blocked

0 · Reply

vu_jade Feb. 18 at 9:02 PM

$GKOS didn’t know you had it in you!

0 · Reply

howardlindzon Feb. 18 at 8:30 PM

$GKOS nice move today...

0 · Reply

ZacksResearch Feb. 18 at 3:57 PM

$GKOS just lit up the growth board 🚀 Q4 revenue surged 36%, and management raised the 2026 sales outlook to $600–$620M as iDose TR and Epioxa fuel momentum. Yes, the loss widened — but top-line acceleration and higher guidance are doing the talking. Is this high-growth story worth the risk? Full breakdown here 👉 https://www.zacks.com/stock/news/2871395/glaukos-misses-q4-earnings-estimates-raises-2026-revenue-outlook?cid=sm-stocktwits-2-2871395-teaser-34004&ADID=SYND_STOCKTWITS_TWEET_2_2871395_TEASER_34004

0 · Reply

stockpicker63 Feb. 18 at 3:34 PM

Whatch today ! $CCJ (Top), $NBIS, $ICLR, $GKOS

0 · Reply

erevnon Feb. 18 at 3:25 PM

Wells Fargo maintains Glaukos $GKOS at Overweight and raises the price target from $122 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Feb 17, 2026, 11:14 PM EST - 22 days ago

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 4:05 PM EST - 22 days ago

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 3, 2026, 10:00 AM EST - 5 weeks ago

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

ACAD AI CNS FSV KTOS MSCI NTRA

Jan 29, 2026, 10:30 PM EST - 5 weeks ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GMAB HLI

Jan 28, 2026, 7:00 AM EST - 6 weeks ago

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Jan 20, 2026, 7:00 AM EST - 7 weeks ago

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Jan 13, 2026, 11:55 PM EST - 2 months ago

Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:05 PM EST - 2 months ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Dec 16, 2025, 7:00 AM EST - 3 months ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 3, 2025, 5:23 PM EST - 3 months ago

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:21 PM EST - 4 months ago

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 3, 2025, 7:00 AM EST - 4 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Oct 30, 2025, 12:06 AM EDT - 4 months ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Glaukos Announces Third Quarter 2025 Financial Results

Oct 20, 2025, 7:10 AM EDT - 5 months ago

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:00 AM EDT - 5 months ago

Glaukos Announces FDA Approval of Epioxa™

Oct 14, 2025, 7:00 AM EDT - 5 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 8, 2025, 7:00 AM EDT - 5 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Sep 25, 2025, 4:05 PM EDT - 5 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Aug 13, 2025, 7:00 AM EDT - 7 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Jul 31, 2025, 5:15 AM EDT - 8 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jun 25, 2025, 4:05 PM EDT - 9 months ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 7:00 AM EDT - 9 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Apr 30, 2025, 10:05 PM EDT - 11 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Glaukos Announces First Quarter 2025 Financial Results

Apr 29, 2025, 11:30 AM EDT - 11 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

$Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 16, 2025, 7:00 AM EDT - 11 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Mar 11, 2025, 7:00 AM EDT - 1 year ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Feb 24, 2025, 9:12 AM EST - 1 year ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 21, 2025, 10:27 AM EST - 1 year ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 4:29 AM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Dec 31, 2024, 8:59 AM EST - 1 year ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 21, 2024, 7:04 AM EST - 1 year ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 2, 2024, 2:29 PM EST - 1 year ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Nov 5, 2024, 12:21 PM EST - 1 year ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Kingofstocks0001 Feb. 24 at 2:43 PM

$GKOS fueled up

0 · Reply

Kingofstocks0001 Feb. 24 at 2:40 PM

$GKOS here comes the rocket

0 · Reply

VickieWaldron193 Feb. 21 at 7:37 AM

$GKOS Glaukos develops ophthalmic surgical devices. Growth depends on procedure adoption. Margins are strong.

0 · Reply

PaulLaurent Feb. 19 at 7:11 AM

0 · Reply

silkroad58 Feb. 18 at 11:38 PM

$CCJ $NBIS $ICLR $GKOS $SPY Your picks are a day late and a dollar short. Blocked

0 · Reply

vu_jade Feb. 18 at 9:02 PM

$GKOS didn’t know you had it in you!

0 · Reply

howardlindzon Feb. 18 at 8:30 PM

$GKOS nice move today...

0 · Reply

ZacksResearch Feb. 18 at 3:57 PM

0 · Reply

stockpicker63 Feb. 18 at 3:34 PM

Whatch today ! $CCJ (Top), $NBIS, $ICLR, $GKOS

0 · Reply

erevnon Feb. 18 at 3:25 PM

Wells Fargo maintains Glaukos $GKOS at Overweight and raises the price target from $122 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 18 at 2:57 PM

$GKOS closes 2025 with strong revenue growth! 🚀 Q4 revenues surged 36% year over year, beating estimates by 6%. Despite an adjusted quarterly loss, momentum in glaucoma and corneal health portfolios sets the stage for 2026 gains. See what could drive GKOS higher this year 👉 https://www.zacks.com/stock/news/2871395/glaukos-misses-q4-earnings-estimates-raises-2026-revenue-outlook?cid=sm-stocktwits-2-2871395-body-34003&ADID=SYND_STOCKTWITS_TWEET_2_2871395_BODY_34003

0 · Reply

erevnon Feb. 18 at 1:10 PM

Needham maintains Glaukos $GKOS at Buy and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Estimize Feb. 18 at 11:03 AM

$GKOS reported -0.28 EPS and 143.12 revenue for Q4. http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_content=GKOS&ut

0 · Reply

erevnon Feb. 18 at 10:27 AM

BTIG reiterates Glaukos $GKOS at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 17 at 9:17 PM

$GKOS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$2.32 down -286.67% YoY • Reported revenue of $143.12M up 35.66% YoY • Glaukos reaffirmed its 2026 net sales guidance, expecting revenue in the range of $600M to $620M based on current foreign currency exchange rates.

0 · Reply

DonCorleone77 Feb. 17 at 7:21 PM

$PANW $CDNS $TOL $GKOS Some notable companies reporting after the market close, with earnings consensus estimates:** - Palo Alto (PANW), consensus 94c - Cadence Design (CDNS), consensus $1.91 - Toll Brothers (TOL), consensus $2.11 - Glaukos (GKOS), consensus (20c)

0 · Reply

Estimize Feb. 17 at 4:00 PM

$GKOS reports after the close, Estimize Consensus +0.02 EPS and +6.48M Revs compared to WS http://www.estimize.com/gkos/fq4-2025?utm_conten

0 · Reply

SuperGreenToday Feb. 10 at 7:34 PM

$GKOS Share Price: $113.89 Contract Selected: Jul 17, 2026 $115 Calls Buy Zone: $12.92 – $15.96 Target Zone: $23.00 – $28.11 Potential Upside: 68% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

VolumeSpreadAnalysis Feb. 4 at 12:05 PM

$GKOS is a medical device company in ophthalmology; its growth is driven by its flagship stent for glaucoma, but payer reimbursement dynamics are critical.

0 · Reply

Kingofstocks0001 Feb. 2 at 3:33 PM

$GKOS great growth

0 · Reply

ZacksResearch Jan. 29 at 2:44 PM

$GKOS up 32.2% in 6 months — but can it sustain the momentum? 💡 🔹 Positioned for growth with interventional glaucoma shift 🔹 Synergies between iDose TR & iStent infinite boosting prospects 🔹 Long-term leverage despite short-term margin pressure Is this a long-term winner? Full analysis here 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-body-30881&ADID=SYND_STOCKTWITS_TWEET_2_2825023_BODY_30881

0 · Reply

ZacksResearch Jan. 29 at 1:44 PM

Hold onto $GKOS — this story isn’t done yet. 👀 Glaukos is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage — even with margin pressure in the mix. That’s a long-term setup investors shouldn’t ignore. See why retaining GKOS still makes sense right now 👉 https://www.zacks.com/stock/news/2825023/heres-why-you-should-retain-glaukos-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2825023-teaser-30877&ADID=SYND_STOCKTWITS_TWEET_2_2825023_TEASER_30877

0 · Reply

Market Cap	5.99B
Revenue (ttm)	507.44M
Net Income (ttm)	-187.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-36.99%
Debt to Equity Ratio	0.00

Volume	508,100
Avg Vol	785,418
Day's Range	N/A - N/A
Shares Out	58.08M
Stochastic %K	14%
Beta	0.70
Analysts	Strong Sell
Price Target	$134.14